House Votes Affirmatively on Bill to Ban or Divest TikTok in US
A House subcommittee previously approved a bill that would either force TikTok’s
TechCrunch’s latest minute covers why a TikTok ban is increasingly likely to happen soon
Author: CapitalCraft
Peak XV Trims Fund Size and Fees in Response to India’s Overheating Market
Here is the rewritten summary:
Peak XV, a top venture firm focused on India and Southeast Asia, streamlines operations by downsizing select funds and
Crypto Exchange-Traded Products (ETPs) Attract Record $3.85 Billion in Inflows Amid Bitcoin’s Surge Past $100,000 Mark
The cryptocurrency market achieved multiple record-breaking milestones last week, as Bitcoin surpassed $100,000 for the first time ever recorded. Ether
Invesco Enters Ether ETF Fee War with 0.25% Charge, Topping VanEck’s Rate
VanEck, an asset manager, has announced a management fee of 0.20% for its investment fund.
Federal Reserve Preferred Inflation Gauge Highlights Key Data Points for Holiday-Shortened Trading Week.
Investors will closely watch the latest inflation data to gauge the Federal Reserve’s future interest rate decisions.
Improving Reliability in Generative AI through Effective Data Ranking and Filtering Techniques
Deasie, a startup creating tools for better text-generating AI control, has secured $2.9 million in initial funding, backed by prominent investors
Bitcoin Price Metrics and Stablecoin Inflows Hint at Rally Continuation on Exchanges
Analysts warn of a “higher-than-normal influx” of stablecoins to exchanges, suggesting traders are gearing up for the next phase of the Bitcoin rally.
Bank of Canada Holds Interest Rates: Official Statement Released
The central bank maintains a stable interest rate of 5% to control inflation and support economic growth. This decision balances the need for low
A Perfect Storm Is Brewing For Bitcoin
Bitcoin ETF options could create a perfect storm for explosive price movements due to their complex derivatives structure. The interplay between spot
MAIA Biotechnology Partners with BeiGene to Provide Clinical Supplies for Upcoming Phase 2 Cancer Trials Across Three Key Indications
Here is a rewritten summary:
Maia Biotechnology Announces Partnership with BeiGene for Groundbreaking Cancer Research
The agreement supports upcoming